Close Menu

NEW YORK (GenomeWeb) – Natera will collaborate with Denmark's Aarhus University on a research study evaluating circulating tumor DNA as a biomarker to detect residual disease, treatment response, and disease recurrence in colorectal cancer patients.

Researchers at Aarhus plan to evaluate 130 patients with stage I-III colorectal cancer who have previously been treated with surgery and chemotherapy.  They will monitor those patients longitudinally, running Natera's ctDNA assay, Signatera, on blood drawn every three months for up to 36 months.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Oct
27
Sponsored by
LGC SeraCare Life Sciences

This webinar brings together an expert panel of stakeholders in cancer diagnostics and clinical care who will discuss the promise and challenges of liquid biopsy technologies in cancer diagnosis, monitoring, and patient care management.